Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.65 |
| ▸ | TLK2 | Q86UE8 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.55 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.55 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 5/20 | 0.51 |
| ▸ | RET | P07949 | 3/20 | 0.51 |
| ▸ | FLT3 | P36888 | 3/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.51 |
| ▸ | PLK4 | O00444 | 2/20 | 0.51 |
| ▸ | PLK1 | P53350 | 2/20 | 0.51 |
| ▸ | JAK3 | P52333 | 2/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5728250 | 1.00 | GSK3B (0.65) | GSK3BTLK2MAPTCDK5PTK2B | |
| SCHEMBL2998484 | 1.00 | GSK3B (0.65) | GSK3BTLK2MAPTCDK5PTK2B | |
| SCHEMBL5849994 | 0.81 | RET (0.55) | GSK3BTLK2CDK5KDRRET | |
| SCHEMBL5367197 | 0.81 | MAPT (0.52) | GSK3BTLK2MAPTCDK5CDK5R1 | |
| SCHEMBL5727946 | 0.81 | PDPK1 (0.55) | GSK3BMAPTKDRRETFLT3 | |
| SCHEMBL14519137 | 0.81 | LRRK2 (0.58) | RETPDGFRBRPS6KA3LRRK2 | |
| SCHEMBL7878729 | 0.81 | LRRK2 (0.58) | RETPDGFRBRPS6KA3LRRK2 | |
| SCHEMBL5727942 | 0.81 | PDPK1 (0.55) | GSK3BMAPTKDRRETFLT3 | |
| SCHEMBL5728661 | 0.81 | RET (0.55) | GSK3BTLK2CDK5KDRRET | |
| SCHEMBL11748696 | 0.79 | GSK3B (1.00) | GSK3BTLK2MAPTPTK2BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2017-06-22 | — | — | US | claimed |
| US-20100173954-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2010-07-08 | — | — | US | claimed |
| EP-2114403-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | Bayer Healthcare, LLC (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008089388-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2008-07-24 | — | — | WO | claimed |
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20100173954-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2010-07-08 | — | — | US | disclosed |
| EP-2114403-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | Bayer Healthcare, LLC (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008089388-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008027013-A2 | COMBINATION OF MTOR ANTAGONIST AND ANGIOGENESIS INHIBITOR FOR THE TREATMENT OF CANCER | NATIONAL CANCER CENTRE (SG) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007059155-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | CDK4, TP53, ABCC1 | GSK3B 1254/4885TLK2 1488/4885MAPT 431/4885 |
| US-20100173954-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | CDK4, TP53, ABCC1 | GSK3B 1254/4885TLK2 1488/4885MAPT 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.